Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Details Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

2006-10-03

2006-10-03

Owens, Amelia A. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S567000, C560S045000, C560S047000, C560S048000, C562S454000, C562S456000, C562S457000

Reexamination Certificate

active

07115662

ABSTRACT:
Disclosed are the compounds of formula Iwherein R is methyl or ethyl; R1is chloro or fluoro; R2is hydrogen or fluoro; R3is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4is hydrogen or fluoro; and R5is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.

REFERENCES:
patent: 3531493 (1970-09-01), Gittos et al.
patent: 3558690 (1971-01-01), Sallmann et al.
patent: 3652762 (1972-03-01), Sallmann et al.
patent: 3895063 (1975-07-01), Sallmann et al.
patent: 4173577 (1979-11-01), Sallmann et al.
patent: 4548952 (1985-10-01), Casas
patent: 5958978 (1999-09-01), Yamazaki et al.
patent: 6291523 (2001-09-01), Fujimoto et al.
patent: 6310099 (2001-10-01), Fujimoto et al.
patent: 6451858 (2002-09-01), Fujimoto et al.
patent: 6727281 (2004-04-01), Fujimoto et al.
patent: 3445011 (1985-06-01), None
patent: 865 788 (1998-09-01), None
patent: WO 94/04484 (1994-03-01), None
patent: WO 96/00716 (1996-01-01), None
patent: WO 97/09977 (1997-03-01), None
Sircar J.C., Curr.Opin.Invest.Drugs, vol. 2 (4), pp. 403-407 (1993).
Englehardt G., Z. Rheumatol, vol. 53, Suppl. 1, p. 68 (1994).
Englehardt G., Eur. J., Clin. Pharmacology, vol. 47 (No. 1) p. A98 (1994).
Brit. J. Pharmacol., vol. 112, Proc. Suppl., p. 183P (1994).
Klein T. et al., Biochemical Pharmacology, vol. 48, No. 8, pp. 1605-1610 (1994).
Mitchell J.A. et al., Proc.Natl.Acad.Sci.USA, vol. 90, pp. 11693-11697 (1994).
Pallapies D. et al., Life Sciences, vol. 57, No. 2, pp. 83-89 (1995).
Pairet M. et al., Proceedings of a conference, Oct. 10-11, 1995, “Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors”, Edited by John Vane et al., pp. 103-119.
Seibert K. et al., Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 23, pp. 125-127 (1995).
Englehardt G., Br.J.Rheumatol. vol. 34, Abstr. Suppl. 1, p. 48 (1995).
Glaser K.B., Inflammopharmacology, vol. 3, pp. 335-345, (1995).
Gierse J.K. et al., Biochem.J., vol. 305, pp. 479-484 (1995).
Prasit P. et al., Med.Chem.Res., vol. 5, pp. 364-374 (1995).
Chan Chi-Chung et al., Journ.Pharmacology and Experimental Therapeutics, vol. 274, pp. 1531-1537 (1995).
Grossman C.J. et al., Inflammation Res., vol. 44, pp. 253-257 (1995).
Glaser K.B. et al., Inflammation Res., vol. 44, Suppl. 3, p. S276 (1995).
Gamage et al., Anti-Cancer Drug Design (vol. 7, pp. 403-414 (1992).
Grossman C.J. et al., Inflammation Res., vol. 44, Suppl. 3, p. S272 (1995).
Warner T.D. et al., Inflammation Res., vol. 44, Suppl. 3, p. S274 (1995).
Terlain B. et al., Presse Med., vol. 24, No. 10, pp. 491-496 (1995).
Gierse J.K. et al., Journ.Biological Chemistry, vol. 271, No. 26, pp. 15810-15814 (1996).
Englehardt G., Z. Rheumatol. vol. 55, Suppl. 1, p. 112 (1996).
Distel M. et al., British Jour. of Rheumatology, vol. 35 (suppl. 1) pp. 68-77 (1996).
Churchill L. et al., Inflammopharmacology, vol. 4, pp. 125-135 (1996).
Steinhilber D., Pharm.Ztg., vol. 141(37), pp. 11-18 (1996).
Vane J.R. et al., Scan.J.Rheumatol. vol. 25 (Suppl. 102) pp. 9-21 (1996).
Matsushita M. et al., Inflamm.Res., vol. 46, pp. 461-466 (1997).
Englehardt G. et al., Biochemical Pharmacology, vol. 51, pp. 21-28 (1996).
Cromlish W.A. et al., Biochemical Pharmacology, vol. 52, pp. 1777-1785 (1996).
Brideau C. et al., Inflamm. Res., vol. 45, pp. 68-74 (1996).
Moser et al., J. Med. Chem., vol. 33, pp. 2358-2368 (1990).
Patrignani P. et al., Journal of Physiology and Pharmacology, vol. 48, 4, pp. 623-631 (1997).
Pairet M. et al., Proceedings of a conference on Mar. 20-21, 1997, “Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential” Edited by John Vane et al., pp. 27-46.
Dammann H.G. et al., Clinical Pharmacology & Therapeutics, vol. 61, p. 162 (1997).
Pairet M. et al., Infamm. Res., vol. 47, Suppl. 2, pp. S93-S101 (1998).
Silvestre J. et al., Drugs of the Future, vol. 23(6), pp. 598-601 (1998).
Giuliano F. et al., Brit. J.Pharmacol., vol. 125, Suppl. 1, 35P (1998).
Simmons D.L. et al., Journal of Lipid Mediators, vol. 6, pp. 113-117 (1993).
Japanese Pharmacol. Ther., vol. 25, No. 8, pp. 2131-2136 (1997).
Japanese Journal of Inflammation, vol. 15, No. 5, pp. 409-411 (1995).
Cryer B. et al., Amer.J.Med., vol. 104, No. 5, pp. 413-421 (1998).
Chemical Abstract 118:80787 (1993).
Chemical Abstracts 104: 109230 (Abstract of DE 3445011).
Griswold et al., Medicinal Research Reviews, vol. 16, No. 2, pp. 181-206 (1996).

Affiliated with

Also associated with

Rating

Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3648632